The New Insight on the Significance of Vascular Endothelial Growth Factor in Anti-angiogenesis Therapy for Diffuse Large B Cell Lymphoma.

Diffuse large B cell lymphoma (DLBCL) is one of the most aggressive hematological diseases. Angiogenesis is one of the important aspects of DLBCL, providing the basics for tumor growth and metastasis. In this review, we discussed the Vascular Endothelial Growth Factor (VEGF) polymorphisms, the role of VEGF expression and angiogenesis in disease pathophysiology, and the association of VEGF and other angiogenesis parameters in the prognosis of this non-Hodgkin lymphoma. A comprehensive literature search was conducted using PubMed, Scopus, and Google Scholar to identify studies related to VEGF and angiogenesis in DLBCL. Keywords included "VEGF," "angiogenesis," "DLBCL," and "anti-angiogenesis therapy." Relevant articles from the past two decades were prioritized for inclusion. Based on the majority of previous studies, VEGF and the higher score of angiogenesis may play a role in the disease's aggressiveness. Seemingly, an abnormal vascular network may assist tumor cells in evading the immune system. Regarding improving anti-angiogenesis therapy, it could be considered one member of the combination treatment for DLBCL. The numerous studies highlighting the significance of angiogenesis in lymphoma, yet failing to achieve substantial improvements in patient survival, underscore the need for further research in this field.